Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cellular and molecular networks governing myelination dynamics in the central nervous system.
Localized PD-1 CAR T therapy reprograms neuroinflammation.
Targeting cannabinoid receptor 1 for multiple sclerosis: molecular docking and dynamic insights of berberine and curcumin as potential therapeutic agents.
Subacute Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine Exposure Induces Neurobehavioral Deficits and Hippocampal Demyelination in Mice.
Astrocytes in Multiple Sclerosis: Getting to the Core.
Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.
Reproductive health in multiple sclerosis patients: overcoming challenges and improving patient care.
Role of CMTM6 in disease pathogenesis and clinical translation potential (Review).
The value of brain age as a transdiagnostic biomarker of neurodegeneration.
Determinants of relapse risk under disease-modifying therapies in multiple sclerosis: an Andersen-Gill Cox regression analysis.
FLAMES presenting as refractory focal status epilepticus: Diagnostic clues in MOG antibody-associated cortical encephalitis.
Bridging the Pregnancy Knowledge Gap: A Real-World Analysis of Medication Use and Drug-Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis.
Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target.
Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorder: Real-World Clinical Outcomes and Safety From a Tertiary Care Center in Northwest India.
Differential Cranial Nerve Susceptibility to Compression by a Giant Cerebellopontine Angle Epidermoid Cyst: A Case Report and Literature Review.
Corrigendum to "CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis" [Neurobiology of Disease 2019 Nov 5; 134:104630].
Virus-induced epithelial lesions during fingolimod: HPV-related genital warts and molluscum contagiosum-case series and literature review.
Acute Effects of Virtual Reality-Based Optokinetic Stimulation: Comparison of Individuals with Multiple Sclerosis With and Without Central Vestibular Dysfunction.
Improving work outcomes in people with multiple sclerosis: A scoping review of non-pharmacological interventions.
Complement C5 inhibitors as add-on rescue treatment in severe AQP4-antibody neuromyelitis optica spectrum disorder attacks: a case series and literature review.
Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.
Skeletal muscle mitochondrial impairment in patients with newly diagnosed multiple sclerosis revealed by ¹H/³¹P magnetic resonance spectroscopy.
Predictors of secondary progressive multiple sclerosis in a real word retrospective cohort: the role of clinical factors and disease-modifying therapy patterns.
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.
Autoimmune small-vessel cerebral vasculitis with refractory SIADH: clinical recovery after V-receptor antagonism (tolvaptan).
Pages
« first
‹ previous
…
895
896
897
898
899
900
901
902
903
…
next ›
last »